|
47 Companies |
|
50 Products |
|
50 Products |
|
66 Mechanisms of Action |
|
0 Trials |
|
978 News |
|
| 12345678910111213...1516» |
- | Trial completion: Radial Extracorporeal Shock Wave Treatment (rESWT) of Myofascial Pain Syndrome in Low Back Pain (clinicaltrials.gov) - Apr 30, 2019
P=N/A, N=46, Completed, Sponsor: University of Sao Paulo
Active, not recruiting --> Completed
- | Trial completion: Antibiotic Administration and Blood Culture Positivity in Severe Sepsis and Septic Shock (clinicaltrials.gov) - Apr 20, 2019
P=N/A, N=330, Completed, Sponsor: University of British Columbia
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Enrollment change, Trial termination: Evaluation of Tolerability and Efficacy of Erythropoietin (EPO) Treatment in Spinal Shock: Comparative Study Versus Methylprednisolone (MP) (clinicaltrials.gov) - Mar 14, 2019
P3, N=10, Terminated, Sponsor: Niguarda Hospital
Active, not recruiting --> Completed N=100 --> 10 | Suspended --> Terminated; Italian Medicines Agency decision
- | Trial completion: Inflammation and the Host Response to Injury (Burns) (clinicaltrials.gov) - Mar 7, 2019
P=N/A, N=280, Completed, Sponsor: Massachusetts General Hospital
N=100 --> 10 | Suspended --> Terminated; Italian Medicines Agency decision Active, not recruiting --> Completed
- | Trial completion: Inflammation and the Host Response to Injury (Trauma) (clinicaltrials.gov) - Mar 7, 2019
P=N/A, N=610, Completed, Sponsor: Massachusetts General Hospital
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | dexmedetomidine / Generic mfg.
Enrollment change, Trial completion date, Trial termination: The Effect of Dexmedetomidine on Microcirculation in Severe Sepsis (clinicaltrials.gov) - Mar 4, 2019
P4, N=12, Terminated, Sponsor: National Taiwan University Hospital
Active, not recruiting --> Completed N=60 --> 12 | Trial completion date: Dec 2018 --> Feb 2018 | Recruiting --> Terminated
- | Phase classification: Programming Implantable Cardioverter Defibrillators in Patients With Primary Prevention Indication (clinicaltrials.gov) - Feb 4, 2019
P=N/A, N=1670, Completed, Sponsor: Abbott Medical Devices
N=60 --> 12 | Trial completion date: Dec 2018 --> Feb 2018 | Recruiting --> Terminated Phase classification: P4 --> P=N/A
- | Enrollment change, Trial completion date, Trial termination, Trial primary completion date: Clinical Trial of Nebulized Hypertonic Saline to Attenuate Post-Traumatic Acute Lung Injury (clinicaltrials.gov) - Dec 20, 2018
P1, N=13, Terminated, Sponsor: Denver Health and Hospital Authority
Phase classification: P4 --> P=N/A N=20 --> 13 | Trial completion date: May 2021 --> Nov 2018 | Recruiting --> Terminated | Trial primary completion date: May 2021 --> Nov 2018; low enrollment and loss of funding
- | dexmedetomidine / Generic mfg.
Enrollment change, Trial completion date, Trial primary completion date: Dexmedetomidine on Microcirculation in Septic Shock (clinicaltrials.gov) - Dec 12, 2018
P4, N=44, Completed, Sponsor: Southeast University, China
N=20 --> 13 | Trial completion date: May 2021 --> Nov 2018 | Recruiting --> Terminated | Trial primary completion date: May 2021 --> Nov 2018; low enrollment and loss of funding N=30 --> 44 | Trial completion date: May 2016 --> May 2017 | Trial primary completion date: Apr 2016 --> Dec 2016
- | Enrollment change, Trial completion date, Trial termination, Trial primary completion date: Lung and Systemic Inflammation in the Critically Ill Patient (clinicaltrials.gov) - Dec 12, 2018
P=N/A, N=8, Terminated, Sponsor: Rigshospitalet, Denmark
N=30 --> 44 | Trial completion date: May 2016 --> May 2017 | Trial primary completion date: Apr 2016 --> Dec 2016 N=18 --> 8 | Trial completion date: Nov 2017 --> Dec 2018 | Recruiting --> Terminated | Trial primary completion date: Nov 2016 --> Dec 2018; Slow enrollment and therefore not possible to reach the estimated enrollment
- | Enrollment closed: Antibiotic Administration and Blood Culture Positivity in Severe Sepsis and Septic Shock (clinicaltrials.gov) - Nov 20, 2018
P=N/A, N=330, Active, not recruiting, Sponsor: University of British Columbia
N=18 --> 8 | Trial completion date: Nov 2017 --> Dec 2018 | Recruiting --> Terminated | Trial primary completion date: Nov 2016 --> Dec 2018; Slow enrollment and therefore not possible to reach the estimated enrollment Recruiting --> Active, not recruiting
- | Leukine (sargramostim) / Partner Therap
Phase classification, Metastases: Radiofrequency Therapy-Induced Endogenous Heat-Shock Proteins With or Without Radiofrequency Ablation or Cryotherapy in Treating Patients With Stage IV Melanoma (clinicaltrials.gov) - Oct 31, 2018
P1, N=11, Completed, Sponsor: Mayo Clinic
Recruiting --> Active, not recruiting Phase classification: P=N/A --> P1
- | Trial primary completion date: Antibiotic Administration and Blood Culture Positivity in Severe Sepsis and Septic Shock (clinicaltrials.gov) - Oct 16, 2018
P=N/A, N=328, Recruiting, Sponsor: University of British Columbia
Phase classification: P=N/A --> P1 Trial primary completion date: Jun 2018 --> Dec 2018
- | Enrollment change, Trial completion date, Trial primary completion date: Pancreatic Exocrine Insufficiency and Pancreatic Enzyme Supplementation in Critically Ill Adult Patients (clinicaltrials.gov) - Sep 6, 2018
P=N/A, N=362, Completed, Sponsor: Shanghai 10th People's Hospital
Trial primary completion date: Jun 2018 --> Dec 2018 N=1200 --> 362 | Trial completion date: Dec 2014 --> Dec 2015 | Trial primary completion date: Dec 2014 --> Dec 2015
- | Trial completion, Phase classification: HEMOSEPSIS: Transpulmonary Thermodilution and Transesophageal Echocardiography in Early Septic Shock (clinicaltrials.gov) - Aug 22, 2018
P4, N=153, Completed, Sponsor: University Hospital, Limoges
N=1200 --> 362 | Trial completion date: Dec 2014 --> Dec 2015 | Trial primary completion date: Dec 2014 --> Dec 2015 Recruiting --> Completed | Phase classification: P3 --> P4
- | Trial completion: ImaCor II: Effects of Hemodynamic Monitoring Using the ImaCor Single Use Transesophageal Echocardiography Probe in Critically Ill Patients (clinicaltrials.gov) - Aug 22, 2018
P=N/A, N=550, Completed, Sponsor: University Hospital Inselspital, Berne
Recruiting --> Completed | Phase classification: P3 --> P4 Active, not recruiting --> Completed
- | Trial completion, Trial completion date, Trial primary completion date: VENUS: Septic Gene Expression Using SeptiCyte (clinicaltrials.gov) - Aug 20, 2018
P=N/A, N=379, Completed, Sponsor: Immunexpress
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial completion date: Aug 2018 --> Dec 2016 | Trial primary completion date: May 2018 --> Aug 2016
- | Trial completion, Enrollment change, Trial primary completion date: The Checklist for Early Recognition and Treatment of Acute Illness (CERTAIN) (clinicaltrials.gov) - Aug 20, 2018
P=N/A, N=5215, Completed, Sponsor: Mayo Clinic
Active, not recruiting --> Completed | Trial completion date: Aug 2018 --> Dec 2016 | Trial primary completion date: May 2018 --> Aug 2016 Recruiting --> Completed | N=15000 --> 5215 | Trial primary completion date: Mar 2018 --> Dec 2017
- | Enrollment change, Trial termination: Cerebral Autoregulation in Non Neurological Critical Patients. (clinicaltrials.gov) - Jun 27, 2018
P=N/A, N=50, Terminated, Sponsor: Althaia Xarxa Assistencial Universitària de Manresa
Recruiting --> Completed | N=15000 --> 5215 | Trial primary completion date: Mar 2018 --> Dec 2017 N=100 --> 50 | Recruiting --> Terminated; Slow recruitment rate
- | Trial completion date, Trial primary completion date: Radial Extracorporeal Shock Wave Treatment (rESWT) of Myofascial Pain Syndrome in Low Back Pain (clinicaltrials.gov) - Jun 14, 2018
P=N/A, N=46, Active, not recruiting, Sponsor: University of Sao Paulo
N=100 --> 50 | Recruiting --> Terminated; Slow recruitment rate Trial completion date: Jan 2015 --> Dec 2018 | Trial primary completion date: Dec 2014 --> Mar 2018
- || ganetespib (ADX-1612) / Aldeyra, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial completion, Trial completion date, Trial primary completion date, Combination therapy, Metastases: Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (clinicaltrials.gov) - Jun 14, 2018
P1, N=9, Completed, Sponsor: Memorial Sloan Kettering Cancer Center
Trial completion date: Jan 2015 --> Dec 2018 | Trial primary completion date: Dec 2014 --> Mar 2018 Active, not recruiting --> Completed | Trial completion date: Jun 2019 --> Jun 2018 | Trial primary completion date: Jun 2019 --> Jun 2018
- | Neo-Synephrine (phenylephrine hydrochloride ophthalmic solution) / Paragon BioTeck, Bausch Health, Akorn
Enrollment change, Trial termination: Phenylephrine Versus Norepinephrine for Septic Shock in Critically Ill Patients (clinicaltrials.gov) - Jun 13, 2018
P4, N=17, Terminated, Sponsor: Vanderbilt University Medical Center
Active, not recruiting --> Completed | Trial completion date: Jun 2019 --> Jun 2018 | Trial primary completion date: Jun 2019 --> Jun 2018 N=75 --> 17 | Recruiting --> Terminated; Slow enrollment; Lack of support and equipoise
- | Leukine (sargramostim) / Partner Therap
Trial completion, Enrollment change, Metastases: Radiofrequency Therapy-Induced Endogenous Heat-Shock Proteins With or Without Radiofrequency Ablation or Cryotherapy in Treating Patients With Stage IV Melanoma (clinicaltrials.gov) - Jun 8, 2018
P=N/A, N=11, Completed, Sponsor: Mayo Clinic
N=75 --> 17 | Recruiting --> Terminated; Slow enrollment; Lack of support and equipoise Active, not recruiting --> Completed | N=23 --> 11
- | ganetespib (ADX-1612) / Aldeyra, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (clinicaltrials.gov) - Jun 6, 2018
P1, N=9, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Active, not recruiting --> Completed | N=23 --> 11 Trial completion date: Jun 2018 --> Jun 2019 | Trial primary completion date: Jun 2018 --> Jun 2019
- | Trial completion date: Effects of Endotoxin in Normal Human Volunteers (clinicaltrials.gov) - Jun 2, 2018
P1, N=198, Completed, Sponsor: National Institutes of Health Clinical Center (CC)
Trial completion date: Jun 2018 --> Jun 2019 | Trial primary completion date: Jun 2018 --> Jun 2019 Trial completion date: Mar 2007 --> May 2018
- ||||||| Trial completion, Trial completion date, Trial primary completion date: Efficacy of Extracorporeal Shockwave Myocardial Revascularization Therapy in Patients With Stable Angina Pectoris (clinicaltrials.gov) - Apr 10, 2018
P3, N=72, Completed, Sponsor: Evgeny Shkolnik, MD
Trial completion date: Mar 2007 --> May 2018 Recruiting --> Completed | Trial completion date: Sep 2016 --> Dec 2017 | Trial primary completion date: Jun 2016 --> Dec 2017
- | Trial completion, Trial completion date: Lactated Ringer Versus Albumin in Early Sepsis Therapy (clinicaltrials.gov) - Apr 6, 2018
P3, N=360, Completed, Sponsor: University of Sao Paulo
Recruiting --> Completed | Trial completion date: Sep 2016 --> Dec 2017 | Trial primary completion date: Jun 2016 --> Dec 2017 Recruiting --> Completed | Trial completion date: Dec 2016 --> Dec 2017
- | Trial completion, Phase classification: Adsorbtion of Cytokines Early in Septic Shock: the ACESS Study (clinicaltrials.gov) - Mar 27, 2018
P, N=20, Completed, Sponsor: Zsolt Molnár, MD, PhD, DEAA
Recruiting --> Completed | Trial completion date: Dec 2016 --> Dec 2017 Recruiting --> Completed | Phase classification: PN/A --> P
- | Trial completion date, Trial termination, Trial primary completion date: The Effect of Erythropietin on Microcircualtory Alteration in Intensive Care Unit Patients With Severe Sepsis (clinicaltrials.gov) - Mar 14, 2018
P=N/A, N=22, Terminated, Sponsor: London Health Sciences Centre
Recruiting --> Completed | Phase classification: PN/A --> P Trial completion date: Sep 2017 --> Mar 2018 | Recruiting --> Terminated | Trial primary completion date: Sep 2017 --> Mar 2018; Lack of recruitment
- || Enrollment closed, Trial completion date: ImaCor II: Effects of Hemodynamic Monitoring Using the ImaCor Single Use Transesophageal Echocardiography Probe in Critically Ill Patients (clinicaltrials.gov) - Mar 7, 2018
P=N/A, N=550, Active, not recruiting, Sponsor: University Hospital Inselspital, Berne
Trial completion date: Sep 2017 --> Mar 2018 | Recruiting --> Terminated | Trial primary completion date: Sep 2017 --> Mar 2018; Lack of recruitment Completed --> Active, not recruiting | Trial completion date: Nov 2017 --> May 2018
- ||| Trial completion, Trial completion date, Trial primary completion date: ImaCor II: Effects of Hemodynamic Monitoring Using the ImaCor Single Use Transesophageal Echocardiography Probe in Critically Ill Patients (clinicaltrials.gov) - Mar 5, 2018
P=N/A, N=550, Completed, Sponsor: University Hospital Inselspital, Berne
Completed --> Active, not recruiting | Trial completion date: Nov 2017 --> May 2018 Recruiting --> Completed | Trial completion date: Jun 2018 --> Nov 2017 | Trial primary completion date: Nov 2017 --> Oct 2017
- | Trial completion date: Control of Major Bleeding After Trauma Study (clinicaltrials.gov) - Mar 3, 2018
P2, N=144, Terminated, Sponsor: Denver Health and Hospital Authority
Recruiting --> Completed | Trial completion date: Jun 2018 --> Nov 2017 | Trial primary completion date: Nov 2017 --> Oct 2017 Trial completion date: Apr 2018 --> Apr 2017
- || Trial completion date, Trial primary completion date: VENUS: Septic Gene Expression Using SeptiCyte (clinicaltrials.gov) - Feb 28, 2018
P=N/A, N=370, Active, not recruiting, Sponsor: Immunexpress
Trial completion date: Apr 2018 --> Apr 2017 Trial primary completion date: Apr 2017 --> May 2018 | Trial completion date: Jun 2017 --> Aug 2018
- | Leukine (sargramostim) / Partner Therap
Trial completion date, Trial primary completion date, Metastases: Radiofrequency Therapy-Induced Endogenous Heat-Shock Proteins With or Without Radiofrequency Ablation or Cryotherapy in Treating Patients With Stage IV Melanoma (clinicaltrials.gov) - Feb 13, 2018
P=N/A, N=23, Active, not recruiting, Sponsor: Mayo Clinic
Trial primary completion date: Apr 2017 --> May 2018 | Trial completion date: Jun 2017 --> Aug 2018 Trial primary completion date: May 2017 --> May 2018 | Trial completion date: May 2017 --> May 2018
- | Phase classification: ISIS-ICD: Inappropriate Shock Reduction wIth PARAD+ Rhythm DiScrimination (clinicaltrials.gov) - Feb 12, 2018
P=N/A, N=1013, Completed, Sponsor: LivaNova
Trial primary completion date: May 2017 --> May 2018 | Trial completion date: May 2017 --> May 2018 Phase classification: P4 --> P=N/A
- | Trial completion, Phase classification: Stress Reduction to Reduce Risk for Arrhythmia in ICD Patients (The RISTA Study) (clinicaltrials.gov) - Jan 10, 2018
P=N/A, N=314, Completed, Sponsor: Yale University
Phase classification: P4 --> P=N/A Recruiting --> Completed | Phase classification: P3 --> PN/A
- | Trial primary completion date: The Checklist for Early Recognition and Treatment of Acute Illness (CERTAIN) (clinicaltrials.gov) - Jan 9, 2018
P=N/A, N=15000, Recruiting, Sponsor: Mayo Clinic
Recruiting --> Completed | Phase classification: P3 --> PN/A Trial primary completion date: Dec 2017 --> Mar 2018
- | Trial completion: Epidemiology, Acute Management, and Outcomes of Patients With Sepsis Presenting to a Referral Hospital in Western Kenya (clinicaltrials.gov) - Jan 5, 2018
P=N/A, N=198, Completed, Sponsor: Duke University
Trial primary completion date: Dec 2017 --> Mar 2018 Active, not recruiting --> Completed
- | Trial completion: CENSER: Early Use of Norepinephrine in Septic Shock Resuscitation (clinicaltrials.gov) - Dec 22, 2017
P=N/A, N=310, Completed, Sponsor: Mahidol University
Active, not recruiting --> Completed Recruiting --> Completed
- | rocuronium / Generic mfg.
Trial completion, Phase classification, Trial primary completion date, Intubation: CURASMUR: Succinylcholine vs Rocuronium for Prehospital Emergency Intubation (clinicaltrials.gov) - Dec 15, 2017
P3, N=1321, Completed, Sponsor: Centre Hospitalier Universitaire de la R
Recruiting --> Completed Recruiting --> Completed | Phase classification: P4 --> P3 | Trial primary completion date: Dec 2016 --> Jul 2016
- | Enrollment change, Trial initiation date, Trial primary completion date: Effect of Different Strategies for Titrating a High MAP on Microcirculation (clinicaltrials.gov) - Dec 14, 2017
P4, N=24, Completed, Sponsor: Southeast University, China
Recruiting --> Completed | Phase classification: P4 --> P3 | Trial primary completion date: Dec 2016 --> Jul 2016 N=20 --> 24 | Initiation date: Sep 2011 --> Mar 2014 | Trial primary completion date: Dec 2014 --> Sep 2016
- | Solu-Cortef (hydrocortisone sodium succinate injection) / Pfizer
Trial completion: ADRENAL: ADjunctive coRticosteroid trEatment iN criticAlly ilL Patients With Septic Shock (clinicaltrials.gov) - Dec 12, 2017
P4, N=3800, Completed, Sponsor: The George Institute
N=20 --> 24 | Initiation date: Sep 2011 --> Mar 2014 | Trial primary completion date: Dec 2014 --> Sep 2016 Active, not recruiting --> Completed
- ||| Trial completion, Phase classification: EUPHRATES: Safety and Efficacy of Polymyxin B Hemoperfusion (PMX) for Septic Shock (clinicaltrials.gov) - Dec 5, 2017
P=N/A, N=450, Completed, Sponsor: Spectral Diagnostics (US) Inc.
Active, not recruiting --> Completed Active, not recruiting --> Completed | Phase classification: P3 --> PN/A
- | HSP Gp96 vaccine / Cure & Sure Biotech
Trial completion: Research for Immunotherapy of Glioblastoma With Autologous Heat Shock Protein gp96 (clinicaltrials.gov) - Nov 17, 2017
P1, N=20, Completed, Sponsor: Cure&Sure Biotech Co., LTD
Active, not recruiting --> Completed | Phase classification: P3 --> PN/A Active, not recruiting --> Completed
- | Trial completion: CULPRIT-SHOCK: Culprit Lesion Only PCI Versus Multivessel PCI in Cardiogenic Shock (clinicaltrials.gov) - Nov 9, 2017
P4, N=706, Completed, Sponsor: University of Luebeck
Active, not recruiting --> Completed Recruiting --> Completed
- | Trial completion, Enrollment change, Trial primary completion date: Patient Centered Cloud-based Electronic System: Ambient Warning and Response Evaluation (ProCCESs AWARE) (clinicaltrials.gov) - Oct 24, 2017
P=N/A, N=7813, Completed, Sponsor: Mayo Clinic
Recruiting --> Completed Active, not recruiting --> Completed | N=12000 --> 7813 | Trial primary completion date: Dec 2016 --> Jun 2016
- | Trial completion: Effects of Endotoxin in Normal Human Volunteers (clinicaltrials.gov) - Oct 18, 2017
P1, N=198, Completed, Sponsor: National Institutes of Health Clinical Center (CC)
Active, not recruiting --> Completed | N=12000 --> 7813 | Trial primary completion date: Dec 2016 --> Jun 2016 Active, not recruiting --> Completed
- | Trial completion, Phase classification, Enrollment change, Trial primary completion date: Effect of Remote Ischemic Conditioning on Trauma Patients With Hemorrhagic Shock (clinicaltrials.gov) - Oct 17, 2017
P=N/A, N=50, Completed, Sponsor: St. Michael's Hospital, Toronto
Active, not recruiting --> Completed Recruiting --> Completed | Phase classification: P1/2 --> PN/A | N=40 --> 50 | Trial primary completion date: May 2017 --> Jan 2017
- | Trial initiation date: Antibiotic Administration and Blood Culture Positivity in Severe Sepsis and Septic Shock (clinicaltrials.gov) - Oct 16, 2017
P=N/A, N=328, Recruiting, Sponsor: University of British Columbia
Recruiting --> Completed | Phase classification: P1/2 --> PN/A | N=40 --> 50 | Trial primary completion date: May 2017 --> Jan 2017 Initiation date: Jun 2013 --> Mar 2014
- | Trial completion, Enrollment change: The Effect of Extracorporeal Shock Wave Therapy on Carpal Tunnel Syndrome (clinicaltrials.gov) - Oct 11, 2017
P=N/A, N=60, Completed, Sponsor: Tri-Service General Hospital
Initiation date: Jun 2013 --> Mar 2014 Recruiting --> Completed | N=50 --> 60